Scala Biodesign, a Tel Aviv, Israel-based biotechnology company which specializes in proteins development, raised USD$5.5M in Seed funding.
The round was led by TLV Partners.
The company intends to use the funds to expand operations and its R&D sector.
Founded by Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), Scala develops algorithms that improve the activity, stability, and cost of proteins. Combining physics-based modeling, AI, and biological data analysis, Scala, which just exited stealth, enables companies to develop new medicines, green production processes, and foods faster and cheaper.
The company, an alumnus of the seventh batch of the Intel Ignite acceleration program, is now working with a small group of early customers, including top-tier pharmaceutical companies.
FinSMEs
11/09/2023